Main Article Content

Authors

Introduction: Cervical cancer is the second most common cancer among women worldwide and the second cause of cancer mortality in women. It has been demonstrated that the process of cervical carcinogenesis displays genetic and environmental epigenetic components. Currently, research is focused on new prognosis markers like oncogene amplification.
Objectives: To perform detection of MYCN, C-MYC, MYCL1, ERBB2, EGFR, and AKT2 amplification. Additionally, to detect human papillomavirus in samples from normal cytology smear, cervical intraepithelial neoplasia (CIN) I, II, and III and cervical cancer patients.
Methods: Papillomavirus (HPV) genotyping by reverse line blot (RLB) performed and gene amplification by detection with real-time PCR with Taqman probes.
Results: HPV was present in 4% of the patients with normal cytology, 48% in CIN I, 63.6% in CIN II, 64% in CIN III, and 70.8% in cervical cancer. Genes amplified in cervical cancer were MYCN (39.1%), ERBB2 (34.7%), and MYCL1 (30.4%); showed higher amplification in high-grade lesions and cervical cancer in relation to low-grade lesions and normal cytology with statistically significant differences. Besides the genes, C-MYC, EGFR, and AKT2 were amplified in samples from patients with cervical cancer by 12%, 18%, and 13%, respectively; we did not find statistical differences.
Conclusion: Higher prevalence of gene amplification and HPV was found in high-grade cervical lesions and cervical cancer.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM.Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. Int J Cancer. 2010; 127: 2893-917.2.Muñoz N, Bosch FX, Sanjose S, Herrero R, Castellsague X,Shah V, et al. Epidemiologic classification of humanpapillomavirus types associated with cervical cancer. N EnglJ Med. 2003, 348: 518-27.3.Savelyeva L, Schwab M. Amplification of oncogenes revisited:from expression profiling to clinical application. CancerLetters. 2001; 167: 115-23.4.Brison O. Gene amplification and tumor progression. BiochimBiophys Acta. 1993; 1155: 25-41.5.Malakh SG, Korshunov A, Stroganov AM, Poltaraus AB. Fastdetection of MYCN copy number Alterations in brain neuronaltumors by real-time PCR. J Clin Lab Anal. 2008; 22: 123-30.6.Mark HF, Feldman D, Das S, Sun CL, Samy M, Lathrop J.HER-2/neu oncogene amplification in cervical cancer Studiedby fluorescent in situ hybridization. Genet Test. 1999; 3: 237-42.7.Kinoshita M, Ikei N, Shin S, Inui S, Hirao T, Aono T.Relationship between human papillomavirus and oncogenes(C-MYC, N-MYC) amplification in human cervical Cancers.Nippon Gan Chiryo Gakkai Shi. 1990; 25: 2828-35.8.van den Brule A, Schouls L. GP5 +/6 +PCR reverse line blotfollowed by enables rapid analysis and high-throughputidentification of human papillomavirus genotype. J ClinMicrobiol. 2002, 40: 779-87.9.Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ,Verheijen RH, Fransen-Daalmeijer N, et al. Distribution of 37HPV types mucosotropic in women with cytologically normalcervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000; 87: 221-7.10. Schiffman MH, Bauer HM, Hoover RN, Glass AG, CadellDM, Rush BB, et al. Epidemiologic evidence showing thathuman papillomavirus infection causes most cervicalintraepithelial neoplasia. J Natl Cancer Inst. 1993; 85: 958-64.11. Cobo F, Concha A, Ortiz M. Human papillomavirus (HPV)type distribution in females with abnormal cervical cytology.a correlation with histological study. Open Virol J. 2009; 3:60-6.12. Cancer Gene Census. Amplified Cancer Genes. Trust SangerInstitute. [February 2010]. Cambridge: URL: http://www.sanger.ac.uk/genetics/CGP/Census/amplification.shtml13. Mitra AB, Murty VVVS, Pratap M, Sodhani P, Chaganti SK.ERBB2 (HER2/neu) oncogene is frequently amplified insquamous cell carcinoma of the uterine cervix. Cancer Res1994; 54: 637-9.14. Baker VV, Hatch KD, Shingleton HM. Amplification of thec-myc proto-oncogene in cervical carcinoma. J Surg Oncol.1988; 39: 225-8.15. Golijow CD, Abba MC, Mouron SA, Gómez MA, Dulout FN.C-MYC gene amplification detected in preinvasiveintraepithelial cervical lesions Int J Gynecol Cancer. 2001;11: 462-5.16. Mao X, Orchard G, Lillington DM, Russell-Jones R, YoungBD, Whittaker SJ. Amplification and overexpression of JUNBis associated with primary cutaneous T-cell lymphoma. Blood.2003; 101: 1513-9.17. Sharma A, Pratap M, Sawhney VM, Khan IU, Bhambhani S,Mitra AB. Frequent amplification of C-erbB2 (HER-2/neu)oncogene in cervical carcinoma as detected by non-fluorescencein situ hybridization technique on paraffin sections. Oncology.1999; 56: 83-7.18. Zhang A, Maner S, Betz R, Angstrom T, Stendahl U, BergmanF, et al. Genetic alterations in cervical carcinomas: Frequentlow-level amplifications of oncogenes are associated withhuman papillomavirus infection. Int J Cancer. 2002; 101:427-33.19. Kersemaekers AM, Fleuren GJ, Kenter GG, Van den BroekLJ, Uljee SM , Hermans J , et al. Oncogene alterations incarcinomas of the uterine cervix: overexpression of theepidermal growth factor receptor is associated with poorprognosis. Clin Cancer Res. 1999; 5: 577-86.20. García JM, García D, Muñoz C, Herrero A, Rodrigo JP,Suárez C, et al. Frequent genetic and biochemical alterationsof the PI 3-K/AKT/PTEN pathway in head and neck squamouscell carcinoma. Int J Cancer. 2004; 114: 242-8.

García, D. A., Briceño, I., Castillo, M., & Aristizábal, F. A. (2024). Detection of gene amplification in MYCN, C-MYC, MYCL1, ERBB2, EGFR, AKT2, and human papilloma virus in samples from cervical smear normal cytology, intraepithelial cervical neoplasia (CIN I, II, III), and cervical cancer. Colombia Medica, 42(2), 144–153. https://doi.org/10.25100/cm.v42i2.765 (Original work published June 14, 2011)

Downloads

Download data is not yet available.